New Frontier in Drugs for Antivirals in Disorders of The Respiratory System.

BACKGROUND COVID-19 is still soaring around the world, and the new delta COVID-19 variant is on the rise and spreading around the world. OBJECTIVE to show development of therapeutic strategy of antiviruses in drugs for antivirals in disorders of the respiratory system, we conduct patent analysis surrounding drugs for antivirals in disorders of the respiratory system. MATERIALS AND METHOD European granted patents filed from January 2002 to June 2021 were analyzed. We use a combination of International patent classification (IPC) "A61p31/12" (antivirals) and "A61p11/00" (drugs for disorders of the respiratory system) to identify relevant European patent documents. RESULTS Our study showed that R&D of drugs for antivirals in disorders of the respiratory systems was decreasing over past 20 years. Chemical drugs show more variety in structures and no a common feature for this drug development. The chemical drugs or herbal medicines were much earlier appeared than biological products in research and development. In addition, large global companies play a leading role in developing kinase inhibitors as chemical drugs. CONCLUSION There are three strategies for developing drugs for antivirals in disorders of the respiratory system, including chemical drugs, herbal medicines or natural products, and biological products. Herbal medicines may provide a new insight and approach for developing drugs for antivirals in disorders of the respiratory system. A combination of chemical drugs and natural products may be a therapeutic method for treating patients with COVID-19.